云南高校图书馆联盟文献共享服务平台- OLAPARIB

OLAPARIB: 作品数：39被引量：48H指数：5; 导出分析报告; 相关领域：医药卫生更多>>; 相关作者：崔凯白煜卢绪章朱志超戚春建更多>>; 相关机构：大连医科大学南京医科大学吉林大学复旦大学附属肿瘤医院更多>>; 相关期刊：《Chinese Medical Journal》《中国处方药》《Signal Transduction and Targeted Therapy》《药学与临床研究》更多>>; 相关基金：国家自然科学基金南京医科大学科技发展基金天津市自然科学基金中国博士后科学基金更多>>

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer:real-world multicenter study: 《Frontiers of Medicine》2024年第6期1026-1034,共9页Jing Li Youguo Chen Mian He Xiaoxiang Chen Hao Wen Yu Kang Kaijiang Liu Ge Lou Xipeng Wang Qinglian Wen Li Wang Zhongqiu Lin; Although olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer,its effectiveness in patients without BRCA mutations...; 关键词：adverse events maintenance therapy OLAPARIB ovarian cancer progression-free survival

Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022:A global perspective: 《World Journal of Gastrointestinal Oncology》2024年第11期4489-4505,共17页Xu Feng Yi-Han Chai Ke-Xin Jiang Wen-Bin Jiang Wen-Chao Chen Yu Pan; the Zhejiang Provincial Medical and Health Science and Technology Program,No.2024KY1109.; BACKGROUND Genetic screening for breast cancer gene 1(BRCA)1/2 mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions.Four to seven percent of pancreatic cancer patients h...; 关键词：OLAPARIB Pancreatic cancer Bibliometric analysis Breast cancer susceptibility gene Poly(adenosine diphosphate-ribose)polymerase

PARP抑制剂Olaparib对非小细胞肺癌细胞的放疗增敏作用及其机制: 《南昌大学学报（医学版）》2024年第4期19-23,28,共6页王彤邱凌平钱肖颖洪卫卫王勇李勇; 江西省自然科学基金资助项目重点项目(20224ACB206026);中国抗癌协会-恒瑞PARP抑制剂肿瘤研究基金(CET SDHRCORP252-3-062);江西省中医药科技计划项目(2022A140)。; 目的探讨聚腺苷二磷酸核糖聚合酶(PARP)抑制剂Olaparib对人非小细胞肺癌(NSCLC)细胞的放疗增敏作用及其可能的发生机制。方法以人NSCLC细胞A549细胞系为研究对象,采用CCK-8实验检测不同药物浓度梯度对细胞的增殖抑制作用。选择对细胞10...; 关键词：非小细胞肺癌聚腺苷二磷酸核糖聚合酶抑制剂 A549肺癌细胞奥拉帕尼放疗增敏 DNA损伤修复

Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients: 《World Journal of Clinical Oncology》2024年第7期848-858,共11页Naveed Syed Ashish Vittalrao Chintakuntlawar Deepti Vilasini Aisha Mohamed Al Salami Riad Al Hasan Imrana Afrooz Kanishka Uttam Chandani Ashok Uttam Chandani Aref Chehal; BACKGROUND Poly(ADP-ribose)polymerase inhibitors(PARPis)are approved as first-line therapies for breast cancer gene(BRCA)-positive,human epidermal growth factor receptor 2-negative locally advanced or metastatic breas...; 关键词：Homologous recombination repair BRCA1 BRCA2 Homologous recombination deficiency Ovarian cancer Breast cancer Poly(ADP-ribose)polymerase inhibitors OLAPARIB DNA double-strand breaks

AKT抑制剂NTQ1062与Olaparib在卵巢癌细胞中的联用研究: 《药学与临床研究》2024年第2期97-102,共6页李月楚周秋华苗雷季晓君马昌友吴舰李念光徐丹; 江苏省自然科学基金(BK20210055)。; 目的:探讨AKT抑制剂NTQ1062和PARP抑制剂Olaparib的对卵巢癌细胞的联用增效可行性及作用机制。方法:研究NTQ1062和Olaparib联用对三种人卵巢癌细胞系(OVCAR-3、TOV-21G、A2780)增殖的影响,并通过Western blot技术检测PI3K/AKT信号通路...; 关键词：卵巢癌 AKT抑制剂 PARP抑制剂联用 DNA损伤同源重组修复

Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway: 《Asian Journal of Andrology》2023年第6期687-694,共8页Hui-Yu Dong Pan Zang Mei-Ling Bao Tian-Ren Zhou Chen-Bo Ni Lei Ding Xu-Song Zhao Jie Li Chao Liang; This work was supported by the National Natural Science Foundation of China(82002718);the Jiangsu Natural Science Foundation(BK20191077);Jiangsu Province Hospital(the First Affiliated Hospital of Nanjing Medical University)Clinical Capacity Enhancement Project(JSPH-MC-2021-12).; Recent studies revealed the relationship among homologous recombination repair(HRR),androgen receptor(AR),and poly(adenosine diphosphate-ribose)polymerase(PARP);however,the synergy between anti-androgen enzalutamide(E...; 关键词：APOPTOSIS enzalutamide nonhomologous end joining OLAPARIB prostate cancer

Clinical utilization of olaparib,a PARP inhibitor,in BRCA1-mutant metastatic acral melanoma: 《Genes & Diseases》2023年第5期1755-1758,共4页Ruixin Jiang Xianbin Liang Ye Tao Ronghui Xia Ming Lei Bin Jiang Robert LJudson-Torres Yanjie Zhang Weizhen Zhang Hanlin Zeng; funded by the National Natural Science Foundation of China(No.82204421,Hanlin Zeng);the Clinical Research Program of 9th People's Hospital,Shanghai Jiao Tong University School of Medicine(No.JYLJ201917,Yanjie Zhang);the Innovative Research Team of High-Level Local Universities in Shanghai,China(No.SHSMU-ZLCX20211700,Ming Lei and Hanlin Zeng).; Acral melanoma(AM)is a rare subtype of cutaneous melanoma linked to poor prognosis,largely due to a lacking of effective targeted therapeutic strategies.Whole-genome sequencing(WGS)data revealed that AM showed a diffe...; 关键词：MELANOMA BRCA1 PD1

PARP-1抑制剂Olaparib对MCF-7乳腺癌的放疗增敏作用及乏氧显像被引量：1: 《中国药理学通报》2023年第9期1668-1674,共7页许阿磊薛杨央陶伟涛王思淇金娟徐慧琴; 国家自然科学基金资助项目(No 81971643)。; 目的探讨PARP抑制剂Olaparib对MCF-7乳腺癌模型的放疗增敏作用,并通过^(18)F-氟赤式硝基咪唑(^(18)F-FETNIM)PET/CT监测Olaparib的放疗增敏效应。方法建立MCF-7乳腺癌模型,按随机数字表法分为对照组、Olaparib组、放疗(IR)组、Olaparib...; 关键词：MCF-7 PARP抑制剂放射治疗放疗敏感性肿瘤乏氧 ^(18)F-FETNIM

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer被引量：1: 《World Journal of Gastrointestinal Surgery》2023年第5期906-916,共11页Yi-Ling Jiang Xue-Yuan Fu Zhi-Hui Yin; BACKGROUND Colorectal cancer(CRC)is a highly prevalent malignancy of the digestive tract worldwide,characterized by a significant morbidity and mortality rate and subtle initial symptoms.Diarrhea,local abdominal pain,...; 关键词：OLAPARIB BEVACIZUMAB Advanced colorectal cancer EFFICACY

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair被引量：2: 《Cancer Biology & Medicine》2022年第8期1150-1171,共22页Yangyang Kong Chang Xu Xiaohui Sun Hao Sun Xiaotong Zhao Ningning He Kaihua Ji Qin Wang Liqing Du Jinhan Wang Manman Zhang Yang Liu Yan Wang Qiang Liu; supported by grants from the National Natural Science Foundation of China(Grant Nos.31670859,81772243,81803172,81803167,31800703,and 31900889);the CAMS Innovation Fund for Medical Science(Grant No.2017-I2M-1-016);the China Postdoctoral Science Foundation(Grant No.2018M630106);the Natural Science Foundation of Tianjin(Grant Nos.18JCYBJC26800,18JCQNJC12300,and 17JCYBJC42700);the Fundamental Research Funds for the Central Universities(Grant No.10023201601602);the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences(Grant Nos.2017-1001-08 and 2018RC310020);the Key R&D Program of Shandong Province(Grant No.2019GSF107056).; Objective:We aimed to investigate the radiosensitizing efficacy of the poly-ADP-ribose polymerase(PARP)inhibitor,olaparib,and the Bloom syndrome protein(BLM)helicase inhibitor,ML216,in non-small cell lung cancer(NSCLC...; 关键词：NSCLC PARP BLM RADIOSENSITIZATION homologous recombination repair

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

OLAPARIB

检索结果分析

下载全文

高级检索检索式检索

时间限定

期刊范围

学科限定全选

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

OLAPARIB

检索结果分析

下载全文

用户登录

高级检索检索式检索